From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, Boroumand S, Stoegner V, Safi A, Perl M, Knoedler S, Pomahac B, Kauke-Navarro M. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases. Frontiers In Immunology 2024, 15: 1276306. PMID: 38715609, PMCID: PMC11074450, DOI: 10.3389/fimmu.2024.1276306.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalHumansImmune Checkpoint InhibitorsNeoplasmsPlastic Surgery ProceduresConceptsImmune checkpoint inhibitorsHead and neck cancerBreast cancerMonoclonal antibodiesCheckpoint inhibitorsSkin cancerReconstructive surgeryNon-surgical treatment strategiesProlonged progression-free survivalSuboptimal treatment plansProgression-free survivalNon-surgical therapySurgical tumor resectionImpaired patient outcomeStandardized treatment algorithmSurgical therapy planningAnti-cancer strategyUnresectable tumorsConventional chemotherapyRemission rateTumor resectionCurative therapyTargeted therapyNeck cancerOncology cases